{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-cancer-hpv/background-information/risk-factors/","result":{"pageContext":{"chapter":{"id":"961e80d0-b721-5756-b1df-56633ce9e5aa","slug":"risk-factors","fullItemName":"Risk factors","depth":2,"htmlHeader":"<!-- begin field 2c341089-5b75-46d0-a7ba-fda39bc60728 --><h2>What are the risk factors for cervical cancer?</h2><!-- end field 2c341089-5b75-46d0-a7ba-fda39bc60728 -->","summary":"","htmlStringContent":"<!-- begin item eb223946-2dfc-44f7-8930-c6215955b7bb --><!-- begin field 6fa1b01e-7152-441c-880b-ba90016ab03f --><ul><li>The two most important risk factors for cervical cancer are:<ul><li>Acquiring infection with human papillomavirus (HPV), particularly types 16 and 18.</li><li>Inadequate cervical screening.</li></ul></li><li>The risk of acquiring HPV infection depends on:<ul><li>The number of sexual partners.</li><li>The age at first sexual intercourse. </li><li>The likelihood that the woman's partner or partners were infected with HPV (determined by the number of their partners).</li><li>Condom use — increased risk of HPV infection if condoms are not used.<ul><li>There is little evidence that other barrier methods (such as diaphragms) reduce the risk of cervical intraepithelial neoplasia (CIN).</li></ul></li></ul></li><li>In women infected with HPV, the following factors increase the risk of progression to cervical cancer:<ul><li>Co-infection with other sexually transmitted infections (STIs), such as herpes simplex, chlamydia or gonococcal infections.</li><li>Smoking.</li><li>High parity (more than five full-term deliveries), and young age (before 17 years) at first birth.</li><li>Family history in a first degree relative.</li><li>Use of the oral contraceptive pill for longer than 5 years.</li></ul></li><li>Women who have conditions associated with immunosuppression are at increased risk of acquiring HPV, persistent infection, precancerous lesions, and invasive cervical cancer. This includes women who: <ul><li>Have HIV – they are more likely to develop persistent HPV infections at an earlier stage, which develop into cancer sooner. </li><li>Take immunosuppressants, for example if they have had an organ transplant, or have inflammatory bowel disease.</li></ul></li><li>The hormonal drug diethylstilbestrol (DES) was used in some women during pregnancy (between 1945 to 1970) to prevent miscarriage. Women whose mothers took DES whilst they were <em>in utero </em>may have an increased risk of invasive cervical cancer.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">RCOG, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">USPSTF, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">FSRH, 2012a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">WHO, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Cancer Research UK, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">AMA, 2016</a>]</p><!-- end field 6fa1b01e-7152-441c-880b-ba90016ab03f --><!-- end item eb223946-2dfc-44f7-8930-c6215955b7bb -->","topic":{"id":"38328a3b-8997-55f8-afac-19e980523812","topicId":"e2dafa6e-4749-48b2-b981-fa906c90d627","topicName":"Cervical cancer and HPV","slug":"cervical-cancer-hpv","lastRevised":"Last revised in September 2020","chapters":[{"id":"417b3c03-a940-5eb6-8b35-698036862be5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b4186a4a-8c1e-51ad-9743-d00be5b18f3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c2a58da0-8965-5522-8b3d-618890f730d3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2a436c60-1809-5f9f-bf39-409fd07e7af5","slug":"changes","fullItemName":"Changes"},{"id":"6b2a8979-8ca9-5087-a80b-ea14445c034a","slug":"update","fullItemName":"Update"}]},{"id":"c207e9ef-e492-5e67-8986-8b48ff76c55f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4e791e8f-015d-58bd-99ec-2689c4baa3e4","slug":"goals","fullItemName":"Goals"},{"id":"b04fb3a0-7363-5d87-b475-a7ad1e7ca9af","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"af911672-6dba-57d0-b3bf-4058c30f91ff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"16911bc4-aa1d-56b2-aaf3-39695a5692f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9c781faa-cf3f-5dcc-b39d-4c10588cbbfb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"713db7a4-b4c8-55f3-8ca0-e5c0db230466","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e32e97af-cb99-5487-8ceb-1d8db9b2fe5f","slug":"types-of-cervical-cancer","fullItemName":"Types of cervical cancer"},{"id":"02013d86-5f8b-50e2-8bbc-9e9e5335f72d","slug":"causes","fullItemName":"Causes"},{"id":"961e80d0-b721-5756-b1df-56633ce9e5aa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4a62390f-59b9-5d3c-ad78-0394d8900138","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5f216154-2a06-5aee-9270-f2388b590979","slug":"prognosis","fullItemName":"Prognosis"},{"id":"98782e4e-b481-5526-803b-b5f18e566c5d","slug":"complications","fullItemName":"Complications"}]},{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a170049-907b-518b-9506-127d186d0a96","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"ae89986b-d468-50ca-b0d4-788dce1cc020","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5aee8849-a5fc-592a-ba2f-161843f6a42e","slug":"cervical-cytology-sample","fullItemName":"Cervical cytology sample"},{"id":"8b13c601-cb6f-536e-a6cc-90001fa3357a","slug":"hpv-screening","fullItemName":"HPV screening"},{"id":"a05197b4-af3e-5fcb-9458-ec6446bb0cb9","slug":"referral","fullItemName":"Referral"}]},{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","fullItemName":"Management","slug":"management","subChapters":[{"id":"3918bf03-5c07-5c8f-bb28-5834e5dc1343","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"5d0f88a0-5a31-5e1f-81ee-89cc202d9885","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"64ce0536-0d7d-554e-afc1-7859f158b82c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f4263e46-d3a8-5853-904f-7c0e9b926a1c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b9af798-d073-5ea1-a174-157b46c68062","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e827e587-3f77-5c14-92f8-58f34c105bbe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"22b0924c-0e7d-5a46-b369-dd38ebbc4a39","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f012ac60-98ba-56b3-838a-7924e3544719","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"102ef6c4-0635-5f17-a33b-e2d83ec751b0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f31eeae-6068-5e2c-8097-3666754f067e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}